OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-12-31-accounts

REGISTERED COMPANY NUMBER: 07476120 (England and Wales) REGISTERED CHARITY NUMBER: 1142803

Trustees' Report and

Unaudited Financial Statements

for the Year Ended 31 December 2023

for

Global Sepsis Alliance

Avalon Accounting Limited 12 Park Lane Tilehurst Reading Berkshire RG31 5DL

Global Sepsis Alliance

Contents of the Financial Statements for the Year Ended 31 December 2023

Page
Trustees' Report 1 to 6
Independent Examiner's Report 7
Statement of Financial Activities 8
Balance Sheet 9 to 10
Notes to the Financial Statements 11 to 16
Detailed Statement of Financial Activities 17 to 18

Global Sepsis Alliance

Trustees' Report for the Year Ended 31 December 2023

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Page 1

Global Sepsis Alliance

Trustees' Report for the Year Ended 31 December 2023

OBJECTIVES AND ACTIVITIES

Objectives and aims

Our charity's purposes as set out in the objects contained in the company's Memorandum of Association are for the public benefit to relieve sickness and promote and protect the physical and mental health of persons suffering from sepsis by: -the provision of financial assistance, support, education, research, and practical advice; and

-increasing awareness and understanding of sepsis and its treatment amongst health professionals, corporations, governmental and non-governmental organizations, and the public.

The aims of our charity are to raise awareness and understanding of sepsis and its treatment and educate a range of audiences, both professional and lay public. Our aims fully reflect the purposes that the charity was set up to further.

Ensuring Our Work Delivers Our Aims

The charity continues to be in its formative years, but we review our aims, objectives, and activities each year. This review outlines what we achieved and the outcomes of our work in the previous 12 months. The review also identifies where each key activity has been successful and the benefits they have brought to those groups of people we were established to help. The review also helps us ensure our aim, objectives, and activities remained focused on our stated purposes. We have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aim and objectives and in planning our future activities. In particular, the Trustees and Executive Committee jointly consider how planned activities will contribute to the aims and objectives they have set.

The Focus of Our Work

Our main objectives for the year 2023 continued to be those activities aimed at raising awareness and understanding of sepsis and its treatment, as well as igniting necessary policy changes and mental shifts in policymakers and governmental institutions, especially those involved in policymaking. These objectives are how we will actively pursue our vision:

A WORLD FREE OF SEPSIS

The strategies we used to meet these objectives included:

-working closely with the WHO and national governments towards having the World Health Assembly (WHA) adopt a resolution on sepsis. This was achieved in May 2017 at the 70th WHA, marking a quantum leap in the global fight against sepsis which was spearheaded by the GSA

-working to get World Sepsis Day officially recognized as a World Health Day by the World Health Organization

-the instigation of the Global Sepsis Awards in 2015, which is now a recurring initiative to highlight sepsis related projects and achievements on a global level each year

-the establishment of World Sepsis Congress in 2016 and World Sepsis Congress Spotlight in 2017. These free online conferences make knowledge about sepsis accessible to all parts of the world

2030 and serves as our North Star

-the development and publication of relevant and timely news posts on our WSD and GSA websites, an email newsletter, as well as the use of social media, especially X (formerly Twitter), Instagram, LinkedIn, TikTok, and Facebook

-sharing stories of people impacted by sepsis on our website and on social media;

-growing the network of the GSA (over 120 members at the end of 2023)

-working towards applying international standards and guidelines, in close connection to the demands of the before-mentioned resolution

Page 2

Global Sepsis Alliance

Trustees' Report

for the Year Ended 31 December 2023

-working in partnership with other organizations and agencies to secure the widest range of initiatives and encouraging action on sepsis.

Briefly mentioned above, of huge significance in 2023 was the 4th World Sepsis Congress - over the course of two days and 16 diverse and highly relevant sessions, 99 speakers, panelists, and moderators from more than 35 countries presented on all aspects of sepsis, including the link to pandemics and AMR, the role of AI (artificial intelligence), ML (machine learning), big data, patient safety, the impact of policy, novel trial design, the latest research, and much more. The congress took place entirely online and participation was free of charge, allowing participants to join from wherever they had an internet connection. The congress was an astonishing success, with more than 15,400 registrations from 187 countries. More than 60% of our audience joined from low- and middle-income countries (LMIC) - the majority of whom could not have afforded to travel to a physical congress to learn about sepsis. All presentations were recorded and continue to be available on our YouTube channel and on Apple Podcasts, easily accessible and free of charge. For the first time ever, the 4th WSC was CME-accredited. We plan to host the 2024 WSC Spotlight in April 2024 and the 5th World Sepsis Congress in April 2025.

Throughout the year, the GSA also supported and promoted other health days with a relationship to sepsis, such as World Hand Hygiene Day, World Patient Safety Day, and virtually all other World Health Days and their respective campaigns. In March, we translated our 'What Is Sepsis?-Video into Korean (it's also available in English, Spanish, Portuguese, French, Italian, Turkish, German, Arabic, and Russian). Towards the end of March, we supported our friends and colleagues from the European Sepsis Alliance hosting their 6th Annual Meeting live from Brussels.

The GSA also kept on supporting and growing its regional sepsis alliances - including their events, such as webinars and physical meetings. Gearing up for World Sepsis Day, we again launched an interactive virtual photo booth - a super fun and engaging way to participate in WSD online.

In addition to facilitating hundreds of events celebrating sepsis awareness and World Sepsis Day all over the world, by inspiring our worldwide network of supporters, providing ideas and material, we also hosted an event in Germany. Said event was titled "The Enactment of the WHO Sepsis on the National and International Level" and held in Berlin in collaboration with the 'Germany Recognizes Sepsis'-coalition, the European Sepsis Alliance, and the Sepsis Stiftung.

Leading up to the event, we were able to receive welcome remarks from Dr. Tedros, WHO Director-General and release the Berlin Declaration. The Berlin Declaration calls for the urgent enforcement of the WHA Resolution on Sepsis and reinvigorated global action on sepsis and has been signed by over 75 organizations from all over the world.

Towards the end of September, we flew to New York for the 78th United Nations General Assembly - precisely, to host the first-ever High-Level Side Event on Sepsis, titled 'Synergizing Global Actions for Sepsis, AMR, and PPPR for Attaining Health Related SDGs'. Serving as a platform for fostering collaboration and innovation in the fight against sepsis and antimicrobial resistance (AMR), and promoting public-private partnerships for health-related SDGs, this pivotal gathering was co-hosted by the Clinton Health Access Initiative, the Global Antibiotic Research & Development Partnership, the Global Sepsis Alliance, the Medical Women's International Association, the Sepsis Stiftung, UNITE, and the Virchow Foundation for Global Health.

In October, we convened a High-Level Luncheon on Sepsis on the Margins of the 2023 World Health Summit, bringing together senior officials from Parliaments, Governments, UN agencies, The G20 & G7 Health and Development Partnership, civil society, the private sector, and academia.

In November - and in collaboration with the Charité - Universitätsmedizin Berlin - we hosted another event, the free live stream of 'Lessons From the COVID-19 Pandemic', featuring Dr. Uzma Syed, and Prof. Konrad Reinhart, as well as a panel discussion on 'Key Lessons on Pandemic Preparedness and Response to Non-Covid Sepsis' with inspiring thought leaders in global health, focusing on the interrelated topics of pandemics, covid, and sepsis.

Over the year, we also released new material on sepsis, such as updated infographics, as well as translated our existing sepsis awareness material to more languages.

Page 3

Global Sepsis Alliance

Trustees' Report

for the Year Ended 31 December 2023

How Our Activities Deliver Public Benefit

Our main activities and who we try to help are described above. All our charitable activities focus on raising awareness and understanding of sepsis and its treatment and this remains our key challenge. All our activities are undertaken to further our charitable purposes for the public benefit. Despite advances in modern medicine, including vaccines, antibiotics, and intensive care, sepsis remains the primary cause of death from infection, including viral infections such as COVID-19. Sepsis, which is often misunderstood by the public as "blood-poisoning" is one of the leading causes of death around the world. Sepsis arises when the body's response to an infection injures its own tissues and organs. It may lead to shock, multiple organ failure, and death, especially if not recognized early and treated promptly. Between one third and one half of patients with sepsis die. In the developing world, sepsis accounts for 60-80% of lost lives per year in childhood, killing more than 6 million neonates and children yearly and is responsible for more than 100,000 cases of maternal sepsis. Every hour, over 1,000 people die from sepsis.

We have a simple message: sepsis must receive utmost priority as a medical emergency, so that all patients can expect to receive basic interventions, including antibiotics and intravenous fluids, within the first hour.

What Examples Exist of Who Has Benefited?

In 2012, the Ropy Staunton Foundation and Global Sepsis Alliance announced that they will unite to fight against sepsis, claims 17 deaths per minute, 24,480 deaths every day and 8-9 million lives annually. Our collaboration has continued into 2021 to create global sepsis awareness and mandates. 12-year-old Ropy scratched his elbow playing school basketball on March 29th, 2012. He soon became unwell and, having previously been sent home from a leading New York hospital, died four days later from unrecognized sepsis.

We formed a Communications Committee under the leadership of Dr Ron Daniels. This Committee was formed to recognize that public awareness is created through action and communication. The Committee will help to further develop ideas and our communications strategy to the press and social media over the whole year and especially around World Sepsis Day. Our efforts on social media are going well, with double-digit growth on Twitter, Facebook, and Instagram. The GSA also has a Quality Improvement Committee (QIC), focusing on research and quality improvement. That includes better protocols in hospitals to detect sepsis earlier, when it is easier to treat and manage.

PLANS FOR FUTURE PERIODS

The charity plans continuing the activities outlined above in the forthcoming years subject to satisfactory funding arrangements. We plan to host another the 2024 World Sepsis Congress Spotlight in April 2024, as well as the 5th World Sepsis Congress in April 2025. All other projects, for example WSD and the GSA Awards, will be continued in 2023.

STRUCTURE, GOVERNANCE AND MANAGEMENT Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006. The organization is a charitable company limited by guarantee, incorporated on December 22nd, 2010 and registered as a charity on June 8th, 2011. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association. In the event of the company being wound up members are required to contribute an amount not exceeding £1.00 GBP.

Recruitment and appointment of new trustees

The Directors of the company are also charity trustees for the purposes of charity law and under the company's Articles are known as the Trustees. The day-to-day management of the company is the responsibility of the members of the Executive Committee who are elected to serve for a period of three years after which they must be re-elected at the next Annual General Meeting. All members of the Executive Committee give their time voluntarily and received no benefits from the charity.

Page 4

Global Sepsis Alliance

Trustees' Report

for the Year Ended 31 December 2023

STRUCTURE, GOVERNANCE AND MANAGEMENT

Induction and training of new trustees

The Trustees are already familiar with the practical work of the charity. A formal induction and training program will be considered as and when new Trustees are appointed. This training will include:

Risk management

The Trustees have conducted a review of the major risks to which the charity is exposed. The charity is still in its formative years and therefore the risk assessment has been confined to an assessment of financial outlook and the ability of the charity to fund its current and future activities. The charity has three current employees and no property or significant investments. However, the need for the charity to conduct a more comprehensive risk assessment (for example to include the completion of a Risk Register and Health and Safety Review) will be conducted annually and a further determination made.

REFERENCE AND ADMINISTRATIVE DETAILS Registered Company number

07476120 (England and Wales)

Registered Charity number

1142803

Registered office

12 Park Lane Tilehurst Reading Berkshire RG31 5DL

Trustees

Mr. Philip Taylor Director Dr. Konrad Anton Reinhart Director Dr. Darren Ron Daniels Director

Company Secretary

Mr. Philip Taylor

Independent Examiner

Avalon Accounting Limited 12 Park Lane Tilehurst Reading Berkshire RG31 5DL

Solicitors

Russell-Cooke LLP 2 Putney Hill London SW15 6AB

Page 5

Global Sepsis Alliance

Trustees' Report for the Year Ended 31 December 2023

REFERENCE AND ADMINISTRATIVE DETAILS

Bankers

Barclays Bank plc Commerzbank Aldermaston Road Fischergasse 10 Tadley 07743 Basingstoke Jena Hampshire Germany RG26 4QA

Executive Committee

Abdulelah Alhawsawi Brett Abbenbroek Daniela Souza Dennis Kredler Emmanuel Nsutebu Imrana Malik Maha Aljuaid Niranjan 'Tex' Kissoon Ron Daniels Shevin Jacob

Board Members

Abdulelah Alhawsawi, Alison Fox-Robichaud, Antonio Artigas, Brett Abbenbroek, Daniela Souza, Dennis Kredler, Emmanuel Nsutebu, Evangelos Giamarellos-Bourboulis, Halima Salisu Kabara, Imrana Malik, Louise Thwaites, Luis Antonio Gorordo Del Sol, Maha Aljuaid, Mitchell Levy, Naoyuki Matsuda, Niranjan 'Tex' Kissoon, Ron Daniels, Shevin Jacob, Tobias Welte, Ulrika Knutsson

Approved by order of the board of trustees on ............................................. and signed on its behalf by:

.......................................................................... Mr. Philip Taylor - Trustee

Page 6

Independent Examiner's Report to the Trustees of Global Sepsis Alliance

Independent examiner's report to the trustees of Global Sepsis Alliance ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2023.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

  1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or 2. the accounts do not accord with those records; or

  2. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or

  3. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Sanjay Swarup

Avalon Accounting Limited 12 Park Lane Tilehurst Reading Berkshire RG31 5DL

Date: .............................................

Page 7

Global Sepsis Alliance

Statement of Financial Activities

for the Year Ended 31 December 2023

2023
Unrestricted
fund
Notes
£
INCOME AND ENDOWMENTS FROM
Donations and legacies
2
273,926
Other trading activities
3
48,431
Total
322,357
EXPENDITURE ON
Raising funds
4
476,889
NET INCOME/(EXPENDITURE)
(154,532)
RECONCILIATION OF FUNDS
Total funds brought forward
630,535
TOTAL FUNDS CARRIED FORWARD
476,003		 2022
Total
funds
£
198,833
55,277
254,110
373,060
(118,950)
749,485
630,535

The notes form part of these financial statements

Page 8

Global Sepsis Alliance

Balance Sheet

31 December 2023

2023
Unrestricted
fund
Notes
£
FIXED ASSETS
Tangible assets
9
10,101
CURRENT ASSETS
Debtors
10
124,329
Cash at bank
346,918
471,247
CREDITORS
Amounts falling due within one year
11
(5,345)
NET CURRENT ASSETS
465,902
TOTAL ASSETS LESS CURRENT
LIABILITIES
476,003
NET ASSETS
476,003
FUNDS
12
Unrestricted funds
476,003
TOTAL FUNDS
476,003		 2022
Total
funds
£
10,162
79,706
548,561
628,267
(7,894)
620,373
630,535
630,535
630,535
630,535

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

The notes form part of these financial statements

continued...

Page 9

Global Sepsis Alliance

Balance Sheet - continued 31 December 2023

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on ............................................. and were signed on its behalf by:

.............................................

Mr. Philip Taylor - Trustee

The notes form part of these financial statements

Page 10

Global Sepsis Alliance

Notes to the Financial Statements for the Year Ended 31 December 2023

1. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

INCOME

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

EXPENDITURE

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

TANGIBLE FIXED ASSETS

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery - 25% on reducing balance
Fixtures and fittings - 25% on reducing balance
Computer equipment - 25% on reducing balance

TAXATION

The charity is exempt from corporation tax on its charitable activities.

FUND ACCOUNTING

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

2. DONATIONS AND LEGACIES

2023 2022
£ £
Donations 273,926 198,833

continued...

Page 11

Global Sepsis Alliance

Notes to the Financial Statements - continued for the Year Ended 31 December 2023

3. OTHER TRADING ACTIVITIES
2023 2022
£ £
Sponsorships 48,431 55,277
4. RAISING FUNDS
RAISING DONATIONS AND LEGACIES
2023 2022
£ £
Postage and stationery 2,810 1,841
Other direct cost 79,760 3,646
Travel subsistence & accommodation 19,053 3,179
Event costs 101,169 96,594
Support costs 274,097 267,800
476,889 373,060
5. SUPPORT COSTS
Information
Management Finance technology
£ £ £
Raising donations and legacies 253,625 597 5,504
Governance
Other Other 2 costs Totals
£ £ £ £
Raising donations and legacies 3,367 1,320 9,684 274,097
6. NET INCOME/(EXPENDITURE)
Net income/(expenditure) is stated after charging/(crediting):
2023 2022
£ £
Depreciation - owned assets 3,367 3,388

continued...

Page 12

Global Sepsis Alliance

Notes to the Financial Statements - continued for the Year Ended 31 December 2023

7. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2023 nor for the year ended 31 December 2022.

TRUSTEES' EXPENSES

There were no trustees' expenses paid for the year ended 31 December 2023 nor for the year ended 31 December 2022.

8. STAFF COSTS

Wages and salaries
The average monthly number of employees during the year was as follows:
Employees		 2023
£
146,054
146,054
2023
-		 2022
£
168,656
168,656
2022
8

No employees received emoluments in excess of £60,000.

9. TANGIBLE FIXED ASSETS

Fixtures
Plant and
and
Computer
machinery
fittings
equipment
£
£
£
COST
At 1 January 2023
838
8,172
19,797
Additions
-
-
3,306
At 31 December 2023
838
8,172
23,103
DEPRECIATION
At 1 January 2023
524
5,861
12,260
Charge for year
78
578
2,711
At 31 December 2023
602
6,439
14,971
NET BOOK VALUE
At 31 December 2023
236
1,733
8,132
At 31 December 2022
314
2,311
7,537		 Totals
£
28,807
3,306
32,113
18,645
3,367
22,012
10,101
10,162

continued...

Page 13

Global Sepsis Alliance

Notes to the Financial Statements-continued Notes to the Financial Statements-continued
for the Year Ended 31 December 2023
10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£ £
Trade debtors 104,590 60,398
Investment 18,639 18,639
VAT 1,100 669
124,329 79,706
11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£ £
Social security and other taxes 3,575 6,209
Accrued expenses 1,770 1,685
5,345 7,894
12. MOVEMENT IN FUNDS
Net
movement At
At 1.1.23 in funds 31.12.23
£ £ £
Unrestricted funds
General fund 630,535 (154,532) 476,003
TOTAL FUNDS 630,535 (154,532) 476,003
Net movement in funds, included in the above are as follows:
Incoming Resources Movement
resources expended in funds
£ £ £
Unrestricted funds
General fund 322,357 (476,889) (154,532)
TOTAL FUNDS 322,357 (476,889) (154,532)

continued...

Page 14

Global Sepsis Alliance

Notes to the Financial Statements - continued

for the Year Ended 31 December 2023

12. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

Net
movement At
At 1.1.22 in funds 31.12.22
£ £ £
Unrestricted funds
General fund 749,485 (118,950) 630,535
TOTAL FUNDS 749,485 (118,950) 630,535
Comparative net movement in funds, included in the above are as follows:
Incoming Resources Movement
resources expended in funds
£ £ £
Unrestricted funds
General fund 254,110 (373,060) (118,950)
TOTAL FUNDS 254,110 (373,060) (118,950)

A current year 12 months and prior year 12 months combined position is as follows:

Unrestricted funds
General fund
TOTAL FUNDS		 Net
movement
At 1.1.22
in funds
£
£
749,485
(273,482)
749,485
(273,482)		 At
31.12.23
£
476,003
476,003

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

Unrestricted funds
General fund
TOTAL FUNDS		 Incoming
resources
£
576,467
576,467		 Resources
Movement
expended
in funds
£
£
(849,949)
(273,482)
(849,949)
(273,482)		 Resources
Movement
expended
in funds
£
£
(849,949)
(273,482)
(849,949)
(273,482)
(273,482)

Page 15

continued...

Global Sepsis Alliance

Notes to the Financial Statements - continued for the Year Ended 31 December 2023

13. RELATED PARTY DISCLOSURES

Insights in Healthcare Ltd provided secretariat services to Global Sepsis Alliance during the year totalling £3,450 (PY - £3,000). Mr. Philip Taylor is common director in both company.

Page 16

Global Sepsis Alliance

INCOME AND ENDOWMENTS
Donations and legacies
Donations
Other trading activities
Sponsorships
Total incoming resources
EXPENDITURE
Raising donations and legacies
Postage and stationery
Other direct cost
Travel subsistence & accommodation
Event costs
Support costs
Management
Wages
Computer Cost
Insurance
Office Rent
Staff welfare
Telephone
Advertising
Office cost
Bookkeeping
Consultancy
Foreign Exchange Loss
Finance
Bank charges
Paypal charges
Information technology
Website development		 Detailed Statement of Financial Activities
for the Year Ended 31 December 2023		 2023
£
273,926
48,431
322,357
2,810
79,760
19,053
101,169
202,792
146,054
14,855
30,546
14,818
274
2,894
5,794
-
924
34,645
2,821
253,625
288
309
597
5,504		 2022
£
198,833
55,277
254,110
1,841
3,646
3,179
96,594
105,260
168,656
5,785
39,276
9,987
79
859
5,146
266
768
2,000
(1,327)
231,495
336
112
448
5,806

This page does not form part of the statutory financial statements

Page 17

Global Sepsis Alliance

Information technology
Other
Plant and machinery
Fixtures and fittings
Computer equipment
Other 2
Subscription
Governance costs
Membership fees
Accountancy fees
Secretary
Total resources expended
Net expenditure		 Detailed Statement of Financial Activities
for the Year Ended 31 December 2023		 2023
£
78
578
2,711
3,367
1,320
4,464
1,770
3,450
9,684
476,889
(154,532)		 2022
£
105
770
2,513
3,388
2,223
19,755
1,685
3,000
24,440
373,060
(118,950)

This page does not form part of the statutory financial statements

Page 18